CL2022003253A1 - Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer - Google Patents

Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer

Info

Publication number
CL2022003253A1
CL2022003253A1 CL2022003253A CL2022003253A CL2022003253A1 CL 2022003253 A1 CL2022003253 A1 CL 2022003253A1 CL 2022003253 A CL2022003253 A CL 2022003253A CL 2022003253 A CL2022003253 A CL 2022003253A CL 2022003253 A1 CL2022003253 A1 CL 2022003253A1
Authority
CL
Chile
Prior art keywords
amyloid
tau
peptide
beta
alzheimer
Prior art date
Application number
CL2022003253A
Other languages
English (en)
Inventor
Barbour Robin
Kinney Gene
Zago Wagner
S Nijjar Tarlochan
Original Assignee
Othair Prothena Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Othair Prothena Ltd filed Critical Othair Prothena Ltd
Publication of CL2022003253A1 publication Critical patent/CL2022003253A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La descripción proporciona composiciones peptídicas y composiciones inmunoterapéuticas que comprenden un péptido amiloide-beta (Abeta) y un péptido tau. La descripción proporciona además métodos para tratar o realizar la profilaxis de la enfermedad de Alzheimer u otras enfermedades con deposición beta-amiloide en un sujeto, que incluyen métodos para depurar depósitos, inhibir o reducir la acumulación de Abeta y/o tau, bloquear la absorción por las neuronas, depurar los amiloides e inhibir la propagación de semillas de tau en un sujeto que padece o tiene riesgo de padecer la enfermedad de Alzheimer u otras enfermedades que comprendan acumulaciones de amiloide-beta y/o tau. Los métodos incluyen administrarles a tales pacientes las composiciones que comprenden un péptido amiloide-beta (Abeta) y un péptido tau.
CL2022003253A 2020-05-19 2022-11-18 Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer CL2022003253A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027150P 2020-05-19 2020-05-19
US202063062903P 2020-08-07 2020-08-07
US202163140917P 2021-01-24 2021-01-24

Publications (1)

Publication Number Publication Date
CL2022003253A1 true CL2022003253A1 (es) 2023-05-26

Family

ID=78708070

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022003253A CL2022003253A1 (es) 2020-05-19 2022-11-18 Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer
CL2025000674A CL2025000674A1 (es) 2020-05-19 2025-03-11 Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2025000674A CL2025000674A1 (es) 2020-05-19 2025-03-11 Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer

Country Status (15)

Country Link
US (6) US20230183304A1 (es)
EP (1) EP4153210A4 (es)
JP (1) JP2023526500A (es)
KR (1) KR20230037501A (es)
CN (1) CN115867304A (es)
AU (1) AU2021276401A1 (es)
BR (1) BR112022023366A2 (es)
CA (1) CA3178760A1 (es)
CL (2) CL2022003253A1 (es)
IL (1) IL298215A (es)
JO (1) JOP20220316A1 (es)
MX (1) MX2022014453A (es)
PH (1) PH12022553234A1 (es)
TW (1) TW202208409A (es)
WO (1) WO2021236809A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7490575B2 (en) 2005-11-08 2009-02-17 Temptime Corporation Combination freeze indicators
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20230364210A1 (en) * 2020-09-17 2023-11-16 Othair Prothena Limited ß-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER’S DISEASE
CN116438191A (zh) * 2020-09-18 2023-07-14 欧萨尔普罗席纳有限公司 治疗阿尔茨海默病之多表位疫苗
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
CU20230023A7 (es) 2023-05-12 2024-12-09 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer
CN120919292A (zh) * 2025-08-04 2025-11-11 首都医科大学宣武医院 用于预防或治疗阿尔茨海默病的Aβ-Tau多表位疫苗及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5840838A (en) 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7632816B2 (en) * 2003-03-28 2009-12-15 New York University Treatment of Alzheimer amyloid deposition
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
US8377875B2 (en) * 2007-01-11 2013-02-19 Ramot At Tel-Aviv University Ltd. Therapeutics based on tau/microtubule dynamics
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
US9738709B2 (en) * 2011-10-21 2017-08-22 Ohio State Innovation Foundation Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018191598A1 (en) 2017-04-13 2018-10-18 Adjuvance Technologies, Inc. Triterpene saponin synthesis, intermediates and adjuvant combinations
US20200164065A1 (en) 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3638298A4 (en) 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA
WO2019070480A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
WO2019070813A2 (en) * 2017-10-03 2019-04-11 The Trustees Of Columbia University In The City Of New York USE OF PEPTIDES AS BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION AND TREATMENT OF A NEUROLOGICAL DISORDER
SG11202001826YA (en) 2017-10-16 2020-03-30 Adjuvance Technologies Inc Triterpene saponin analogues
WO2022032166A1 (en) * 2020-08-07 2022-02-10 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
TW202208409A (zh) 2022-03-01
KR20230037501A (ko) 2023-03-16
BR112022023366A2 (pt) 2023-05-02
WO2021236809A2 (en) 2021-11-25
US20230183304A1 (en) 2023-06-15
CL2025000674A1 (es) 2025-07-11
US20250282838A1 (en) 2025-09-11
US11945849B2 (en) 2024-04-02
US20230322876A1 (en) 2023-10-12
EP4153210A2 (en) 2023-03-29
AU2021276401A1 (en) 2022-12-15
US11965005B2 (en) 2024-04-23
PH12022553234A1 (en) 2024-02-12
US11952406B2 (en) 2024-04-09
CN115867304A (zh) 2023-03-28
WO2021236809A3 (en) 2021-12-30
MX2022014453A (es) 2023-02-09
US20230312662A1 (en) 2023-10-05
US20240343769A1 (en) 2024-10-17
JOP20220316A1 (ar) 2022-11-20
US12247056B2 (en) 2025-03-11
CA3178760A1 (en) 2021-11-25
IL298215A (en) 2023-01-01
US20230295254A1 (en) 2023-09-21
JP2023526500A (ja) 2023-06-21
EP4153210A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
CL2022003253A1 (es) Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer
MX2023001503A (es) Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer.
AR122127A1 (es) VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
MX2023003008A (es) Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer.
Magga et al. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
AR122129A1 (es) Vacuna de tau para el tratamiento de la enfermedad de alzheimer
MX384227B (es) Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.
MX2021000580A (es) Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genetica y para eliminar o reducir las inmunoglobulinas.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
Soumyakrishnan et al. Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFβ1/smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis
UY27721A1 (es) Anticuerpos humanizados que reconocen el peptido amiloide beta.
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
Castillo-Carranza et al. Tau aggregates as immunotherapeutic targets
CR8095A (es) Anticuerpos humanizados que reconocen el cuerpo beta amiloideo
MX2024005899A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
Cole et al. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
MX2022010402A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2022010394A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.